One such mechanism is the upregulation of immune checkpoint molecules, such as PD-L1, which interacts with its receptor PD-1 on TILs, leading to T cell exhaustion and impaired anti-tumor responses [56]. The gene discussed is PDCD1; the disease is neoplasm.